Spectral lifts revenue
TORONTO – Spectral Diagnostics Inc. raises revenue on increased sales of its Endotoxin Activity Assay, used for measuring endotoxin levels in the blood. For the year ended December 31 2008, the company lifted sales to $3,011,000, a modest increase from $2,993,000 in 2007. However, net income declined throughout the year, culminating in a loss of $1,666,000 or $0.06 a share.
